dec-3c-en-2-one | 881650-04-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: dec-3c-en-2-one
• 英文别名: Dec-3c-en-2-on；3-Decen-2-one, (3Z)-；(Z)-dec-3-en-2-one
• CAS: 881650-04-0
• 化学式: C₁₀H₁₈O
• 分子量: 154.252
• InChiKey: JRPDANVNRUIUAB-HJWRWDBZSA-N

物化性质

• 沸点：
  85-87 °C(Press: 11 Torr)
• 密度：
  0.8397 g/cm3

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  11
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  dec-3c-en-2-one 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 cis-3-Decen-2-ol
  参考文献：
  名称：

  Nutrient Support in Hematopoietic Cell Transplantation

  摘要：

  High‐dose cytoreduction and hematopoietic stem cell infusion form the basis for treatment of hematologic cancers, defects or failure of hematopoiesis, and some solid tumors. As an antitumor therapy, allogeneic hematopoietic cell transplantation (HCT) is superior to autologous HCT by induction of a graft‐us‐tumor effect. However, recipients of allografts suffer higher transplant‐related mortality owing to graft‐us‐host disease (GVHD). Nutrition support research must recognize that HCT is a heterogeneous modality whose short and long‐term outcomes are affected by transplant type, preparative regimens, diagnosis, disease stage, age, and nutritional status. The field of HCT will diversify further as lower dose cytoreduction and mixed chimerism grafts allow expansion of the technique to older patients and to other diseases. (journal of Parenteral and Enteral Nutrition 25:219–228, 2001)

  DOI：

  10.1177/0148607101025004219
• 作为产物：
  描述：

  dec-3-yn-2-one 在 palladium on activated charcoal 、 Lindlar's catalyst 、 乙醇 作用下， 生成 dec-3c-en-2-one
  参考文献：
  名称：

  Nutrient Support in Hematopoietic Cell Transplantation

  摘要：

  High‐dose cytoreduction and hematopoietic stem cell infusion form the basis for treatment of hematologic cancers, defects or failure of hematopoiesis, and some solid tumors. As an antitumor therapy, allogeneic hematopoietic cell transplantation (HCT) is superior to autologous HCT by induction of a graft‐us‐tumor effect. However, recipients of allografts suffer higher transplant‐related mortality owing to graft‐us‐host disease (GVHD). Nutrition support research must recognize that HCT is a heterogeneous modality whose short and long‐term outcomes are affected by transplant type, preparative regimens, diagnosis, disease stage, age, and nutritional status. The field of HCT will diversify further as lower dose cytoreduction and mixed chimerism grafts allow expansion of the technique to older patients and to other diseases. (journal of Parenteral and Enteral Nutrition 25:219–228, 2001)

  DOI：

  10.1177/0148607101025004219

文献信息

• [DE] ANSTRICHMITTEL ENTHALTEND POLYMERISATTEILCHEN ENTHALTEND AKTIVE VERBINDUNGEN MIT SPEZIELLER SUBSTRATANHAFTUNG<br/>[EN] COATING COMPOUNDS CONTAINING POLYMER PARTICLES CONTAINING ACTIVE COMPOUNDS WITH A PARTICULAR CAPACITY FOR ADHERING TO SUBSTRATES<br/>[FR] ENDUITS CONTENANT DES PARTICULES POLYMERES QUI COMPORTENT DES COMPOSES ACTIFS ADHERANT PARTICULIEREMENT BIEN AU SUBSTRAT
  申请人：BASF AG

  公开号：WO2006024360A1

  公开（公告）日：2006-03-09

  Die vorliegende Erfindung betrifft Anstrichmittel enthaltend Polymerisatteilchen aus einer polymeren Matrix und einem aktiven Wirkstoff mit einer speziellen Substratanhaftung an Oberflächen und einer guten Formulierbarkeit und die Verwendung dieser Anstrichmittel als Abwehrstoff (Repellent) gegen Hunde, Katzen und Mauerspinnen. Der aktive Wirkstoff wird aus der Zusammensetzung kontrolliert freigesetzt.

  这项发明涉及包含聚合物基质和活性成分的聚合物微粒涂料，具有对表面的特殊基质附着性和良好的配方能力，并将这些涂料用作狗、猫和墙蜘蛛的驱逐剂。活性成分被控制释放。
• Martin, Annales de Chimie (Cachan, France), 1959, vol. <13>1, p. 541,561
  作者：Martin

  DOI：——

  日期：——
• Nutrient Support in Hematopoietic Cell Transplantation
  作者：Polly Lenssen、Barbara Bruemmer、Saundra N. Aker、George B. McDonald

  DOI：10.1177/0148607101025004219

  日期：2001.7

  High‐dose cytoreduction and hematopoietic stem cell infusion form the basis for treatment of hematologic cancers, defects or failure of hematopoiesis, and some solid tumors. As an antitumor therapy, allogeneic hematopoietic cell transplantation (HCT) is superior to autologous HCT by induction of a graft‐us‐tumor effect. However, recipients of allografts suffer higher transplant‐related mortality owing to graft‐us‐host disease (GVHD). Nutrition support research must recognize that HCT is a heterogeneous modality whose short and long‐term outcomes are affected by transplant type, preparative regimens, diagnosis, disease stage, age, and nutritional status. The field of HCT will diversify further as lower dose cytoreduction and mixed chimerism grafts allow expansion of the technique to older patients and to other diseases. (journal of Parenteral and Enteral Nutrition 25:219–228, 2001)